Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine

M. Rodolfo, C. Zilocchi, B. Cappetti, G. Parmiani, C. Melani, M. P. Colombo

Research output: Contribution to journalArticle

Abstract

The colon adenocarcinoma C26, carrying two endogenous tumor-associated antigens (TAA) recognized by CTL, has been transduced with the gene coding for the human folate receptor α (FRα) as an additional antigen in order to study the efficacy of vaccination against a tumor expressing multiple antigens. A dicistronic vector was used to transduce the IL-12 genes to create C26/IL-12FRα that has been used as a cellular vaccine to treat mice bearing lung metastases of C26/FRα. After vaccination mice were partially splenectomized and splenic lymphocytes frozen and used retrospectively to study in vitro CD8 T cell response related to the treatment outcome. Vaccination cured 50% of mice and the effect was CD8 T cell dependent. Mice either cured (responders) or not cured (nonresponders) by vaccination developed tumor-specific CTL. However, analysis of CTL specificity and pCTL frequencies revealed that responders had a predominant CTL activity against endogenous C26-related tumor antigens, whereas nonresponders had CTL that recognized preferentially the FRα antigen. CD8 from responder mice were characterized to release high levels of granulocyte-macrophage (GM)-CSF upon antigen stimulation. Tumors obtained from mice that died despite vaccination lost expression of the FRα transgene but maintained expression of endogenous C26 antigens. Immunoselection against FRα antigen was not observed in tumors from non-vaccinated controls and from CD8-depleted vaccinated mice. Down-regulation of FRα antigen expression was due, at least in part, to methylation of retroviral vector long terminal repeat promoter since FRα expression was partially restored, ex vivo, by treatment with 5-aza-2'-cell-mediated immunoselection and production of GM-CSF are determining factors for the efficacy of tumor vaccines.

Original languageEnglish
Pages (from-to)865-872
Number of pages8
JournalGene Therapy
Volume6
Issue number5
DOIs
Publication statusPublished - May 1999

Fingerprint

Cancer Vaccines
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Interleukin-12
Folic Acid
Genetic Therapy
Vaccination
Antigens
Antigen Receptors
Granulocytes
Neoplasms
Macrophages
T-Lymphocytes
Terminal Repeat Sequences
Transgenes
Methylation
Genes
Colon
Adenocarcinoma
Down-Regulation

Keywords

  • CTL
  • Cytokine gene transfer
  • Tumor immunity

ASJC Scopus subject areas

  • Genetics

Cite this

Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine. / Rodolfo, M.; Zilocchi, C.; Cappetti, B.; Parmiani, G.; Melani, C.; Colombo, M. P.

In: Gene Therapy, Vol. 6, No. 5, 05.1999, p. 865-872.

Research output: Contribution to journalArticle

@article{9895e8e450844c7998507baa99c381c8,
title = "Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine",
abstract = "The colon adenocarcinoma C26, carrying two endogenous tumor-associated antigens (TAA) recognized by CTL, has been transduced with the gene coding for the human folate receptor α (FRα) as an additional antigen in order to study the efficacy of vaccination against a tumor expressing multiple antigens. A dicistronic vector was used to transduce the IL-12 genes to create C26/IL-12FRα that has been used as a cellular vaccine to treat mice bearing lung metastases of C26/FRα. After vaccination mice were partially splenectomized and splenic lymphocytes frozen and used retrospectively to study in vitro CD8 T cell response related to the treatment outcome. Vaccination cured 50{\%} of mice and the effect was CD8 T cell dependent. Mice either cured (responders) or not cured (nonresponders) by vaccination developed tumor-specific CTL. However, analysis of CTL specificity and pCTL frequencies revealed that responders had a predominant CTL activity against endogenous C26-related tumor antigens, whereas nonresponders had CTL that recognized preferentially the FRα antigen. CD8 from responder mice were characterized to release high levels of granulocyte-macrophage (GM)-CSF upon antigen stimulation. Tumors obtained from mice that died despite vaccination lost expression of the FRα transgene but maintained expression of endogenous C26 antigens. Immunoselection against FRα antigen was not observed in tumors from non-vaccinated controls and from CD8-depleted vaccinated mice. Down-regulation of FRα antigen expression was due, at least in part, to methylation of retroviral vector long terminal repeat promoter since FRα expression was partially restored, ex vivo, by treatment with 5-aza-2'-cell-mediated immunoselection and production of GM-CSF are determining factors for the efficacy of tumor vaccines.",
keywords = "CTL, Cytokine gene transfer, Tumor immunity",
author = "M. Rodolfo and C. Zilocchi and B. Cappetti and G. Parmiani and C. Melani and Colombo, {M. P.}",
year = "1999",
month = "5",
doi = "10.1038/sj.gt.3300874",
language = "English",
volume = "6",
pages = "865--872",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine

AU - Rodolfo, M.

AU - Zilocchi, C.

AU - Cappetti, B.

AU - Parmiani, G.

AU - Melani, C.

AU - Colombo, M. P.

PY - 1999/5

Y1 - 1999/5

N2 - The colon adenocarcinoma C26, carrying two endogenous tumor-associated antigens (TAA) recognized by CTL, has been transduced with the gene coding for the human folate receptor α (FRα) as an additional antigen in order to study the efficacy of vaccination against a tumor expressing multiple antigens. A dicistronic vector was used to transduce the IL-12 genes to create C26/IL-12FRα that has been used as a cellular vaccine to treat mice bearing lung metastases of C26/FRα. After vaccination mice were partially splenectomized and splenic lymphocytes frozen and used retrospectively to study in vitro CD8 T cell response related to the treatment outcome. Vaccination cured 50% of mice and the effect was CD8 T cell dependent. Mice either cured (responders) or not cured (nonresponders) by vaccination developed tumor-specific CTL. However, analysis of CTL specificity and pCTL frequencies revealed that responders had a predominant CTL activity against endogenous C26-related tumor antigens, whereas nonresponders had CTL that recognized preferentially the FRα antigen. CD8 from responder mice were characterized to release high levels of granulocyte-macrophage (GM)-CSF upon antigen stimulation. Tumors obtained from mice that died despite vaccination lost expression of the FRα transgene but maintained expression of endogenous C26 antigens. Immunoselection against FRα antigen was not observed in tumors from non-vaccinated controls and from CD8-depleted vaccinated mice. Down-regulation of FRα antigen expression was due, at least in part, to methylation of retroviral vector long terminal repeat promoter since FRα expression was partially restored, ex vivo, by treatment with 5-aza-2'-cell-mediated immunoselection and production of GM-CSF are determining factors for the efficacy of tumor vaccines.

AB - The colon adenocarcinoma C26, carrying two endogenous tumor-associated antigens (TAA) recognized by CTL, has been transduced with the gene coding for the human folate receptor α (FRα) as an additional antigen in order to study the efficacy of vaccination against a tumor expressing multiple antigens. A dicistronic vector was used to transduce the IL-12 genes to create C26/IL-12FRα that has been used as a cellular vaccine to treat mice bearing lung metastases of C26/FRα. After vaccination mice were partially splenectomized and splenic lymphocytes frozen and used retrospectively to study in vitro CD8 T cell response related to the treatment outcome. Vaccination cured 50% of mice and the effect was CD8 T cell dependent. Mice either cured (responders) or not cured (nonresponders) by vaccination developed tumor-specific CTL. However, analysis of CTL specificity and pCTL frequencies revealed that responders had a predominant CTL activity against endogenous C26-related tumor antigens, whereas nonresponders had CTL that recognized preferentially the FRα antigen. CD8 from responder mice were characterized to release high levels of granulocyte-macrophage (GM)-CSF upon antigen stimulation. Tumors obtained from mice that died despite vaccination lost expression of the FRα transgene but maintained expression of endogenous C26 antigens. Immunoselection against FRα antigen was not observed in tumors from non-vaccinated controls and from CD8-depleted vaccinated mice. Down-regulation of FRα antigen expression was due, at least in part, to methylation of retroviral vector long terminal repeat promoter since FRα expression was partially restored, ex vivo, by treatment with 5-aza-2'-cell-mediated immunoselection and production of GM-CSF are determining factors for the efficacy of tumor vaccines.

KW - CTL

KW - Cytokine gene transfer

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=0032980885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032980885&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3300874

DO - 10.1038/sj.gt.3300874

M3 - Article

C2 - 10505112

AN - SCOPUS:0032980885

VL - 6

SP - 865

EP - 872

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 5

ER -